Tag Archive for: biotech

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

/in

Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors 25 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical […]

Read more

The ‘must-attend’ Healthcare conferences of Q1 & Q2 2023

/in

… And just like that it’s ANOTHER new year! If you are still gathering your thoughts on how best to maximise your time in 2023, allow us to flag some of the most impactful and innovative conferences in Life Sciences. The Optimum team really enjoyed being back in person for the majority of the conferences […]

Read more

STORM Therapeutics Expands R&D Leadership Team

/in

Matthew Fyfe joins as Senior Vice President of Therapeutics Beth Thomas promoted to Vice President of Medicinal Chemistry 10 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fyfe […]

Read more

Novo Holdings participates in portfolio company Amolyt Pharma’s $138 million financing

/in

Amolyt is developing therapeutic peptides for rare endocrine and related diseases, including AZP-3601 (eneboparatide) for hypoparathyroidism Proceeds will fund the Phase 3 programme for hypoparathyroidism, as well as its growing endocrine pipeline Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, has announced it has invested in a €130 million (approx. $138 million) […]

Read more

Novo Holdings invests in proteomics technology company, Evosep

/in

COPENHAGEN, DENMARK — Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use. The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep’s standardised liquid chromatography platform. The new […]

Read more